Since CASP1 is significantly overexpressed in AML and Cytarabine-resistant cells, and is associated with poor prognosis, we inhibited CASP1 with Caspase-1 specific inhibitor Belnacasan to investigate its role. The gene discussed is CASP1; the disease is acute myeloid leukemia.